Shareholder Tools
Briefcase Printed Materials Email Alerts Download Center snapshot RSS


+ 0.10
4:00 PM ET on 20 Oct 2016
Delayed at least 20 minutes.
Provided by eSignal.
Stock price graph

Company Profile

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. This focus includes a commitment to providing grants to support research and education in the disease state including the funding of an ongoing outcomes trial.

Vascepa® (icosapent ethyl), Amarin's first FDA-approved product, is an ultra-pure, EPA-only omega-3 fatty acid product available by prescription. For more information about Vascepa visit For more information about Amarin visit

In July 2012, Vascepa received FDA approval in the United States for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia and is now available by prescription. The triglyceride lowering effect of Vascepa® is not associated with increases in LDL-C, bad cholesterol. The only reported adverse reaction with an incidence >2% and greater than placebo in Vascepa treated patients was arthralgia (2.3% for Vascepa vs. 1.0% for placebo).

If you are reporting an adverse event or product complaint, please email or call the Amarin Call Center at 1 855 VASCEPA.

See important safety information about Vascepa

See full prescribing information for Vascepa

Amarin is conducting a cardiovascular outcomes study designed to evaluate the efficacy of Vascepa® in reducing cardiovascular events in a high-risk patient population on statin therapy called the REDUCE-IT trial.

Amarin is headquartered in Dublin, Ireland. In the U.S., the company's office is in Bedminster, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN").

View all »Annual Meeting Materials

25 Feb 2016
Form 10-K
2 May 2016
Proxy 2016

View all »   RSSRecent Releases

12 Sep 2016
Amarin's REDUCE-IT Cardiovascular Outcomes Study of Vascepa to Continue as Planned at Recommendation of Independent Data Monitoring Committee

7 Sep 2016
Amarin to Present at the Rodman & Renshaw 18th Annual Global Investment Conference


Company Registrars

Citi - Depositary Receipt Services
388 Greenwich Street
14th Floor
New York, NY 10013

PO Box 4630,
Aspect House,
Spencer Road,
Lancing, West Sussex, BN99 6QQ

Investor Relations Contacts

Amarin Corporation plc
t: 908 719 1315